Please login to the form below

Not currently logged in

Sanofi gets EU OK for Ablynx flagship drug Cablivi

EMA clears the drug to treat adults with aTTP


Sanofi has EMA approval for its acquired thrombotic thrombocytopenic purpura (aTTP) therapy Cablivi, the main asset behind its €9.3bn acquisition of Belgian biotech Ablynx in January.

The EU regulator has cleared Cablivi (caplacizumab) for adults with aTTP, and Sanofi says that the drug is the first in Europe to be approved specifically for the rare blood-clotting disorder, which causes extensive clot formation in small blood vessels around the body, starving organs of oxygen. The company is also due to hear from the US FDA on its application by 6 February.

At the moment, people with aTTP have to be treated with daily plasma exchange (PEX) and immunosuppressive drugs, and are still a high risk of serious breakthrough attacks that can be fatal in around 20% of cases. In the phase III HERCULES trial, treatment with Cablivi resulted in a significantly shorter time to platelet count response – the primary endpoint – as well as a significant reduction in aTTP-related deaths compared to PEX and immunosuppression.

There’s no word on the cost of the medicine just yet, but analysts at Jefferies have previously suggested that if the price is pitched right Cablivi could be a game-changer in aTTP treatment and generate sales upwards of $500m a year. Prior to its takeover, Ablynx had been suggesting sales of more than €1bn were possible at peak.

Sanofi reckons there are around 7,500 patients with aTTP across the US, the EU and Japan. It has indicated it intends to launch Cablivi in its first EU market – likely Germany – later this year.

The new drug is the first new product to come from Sanofi’s push into rare disease therapies and specifically rare blood disorders, which was also behind its $11.6bn acquisition of Bioverativ earlier this year which added two marketed haemophilia drugs as well as a pipeline of blood disorder products including genome editing drugs and gene therapies.

“The approval of Cablivi provides new hope for people diagnosed with aTTP, who to date have faced a very difficult disease with limited treatment options,” commented Bill Sibold, head of Sanofi’s Genzyme rare disease unit.

“This approval is the next step towards our goal of becoming the leading rare blood disorders company in the industry.”

Article by
Phil Taylor

3rd September 2018

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company
VCCP Health

We’re the challenger agency for challenger brands. Brands with a point to prove. Rx, OTC and wellness brands run by...

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....